217 related articles for article (PubMed ID: 37010535)
1. Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Yu JM; Chen WM; Shia BC; Wu SY
Eur J Clin Pharmacol; 2023 May; 79(5):687-700. PubMed ID: 37010535
[TBL] [Abstract][Full Text] [Related]
2. Optimizing statin therapy for primary prevention of cardiovascular disease in type 2 diabetes mellitus patients
Yu JM; Chen WM; Shia BC; Wu SY
Diab Vasc Dis Res; 2023; 20(6):14791641231214507. PubMed ID: 37933122
[TBL] [Abstract][Full Text] [Related]
3. Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus.
Yu JM; Chen WM; Shia BC; Wu SY
Curr Atheroscler Rep; 2023 Sep; 25(9):619-628. PubMed ID: 37515725
[TBL] [Abstract][Full Text] [Related]
4. Optimal statin use for prevention of sepsis in type 2 diabetes mellitus.
Sun M; Tao Y; Chen WM; Wu SY; Zhang J
Diabetol Metab Syndr; 2023 Apr; 15(1):75. PubMed ID: 37072863
[TBL] [Abstract][Full Text] [Related]
5. Effects of Statin Dose, Class, and Use Intensity on All-Cause Mortality in Patients with Type 2 Diabetes Mellitus.
Yu JM; Chen WM; Chen M; Shia BC; Wu SY
Pharmaceuticals (Basel); 2023 Mar; 16(4):. PubMed ID: 37111264
[TBL] [Abstract][Full Text] [Related]
6. Risk of incident diabetes among patients treated with statins: population based study.
Carter AA; Gomes T; Camacho X; Juurlink DN; Shah BR; Mamdani MM
BMJ; 2013 May; 346():f2610. PubMed ID: 23704171
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
8. A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class.
Hoffman KB; Kraus C; Dimbil M; Golomb BA
PLoS One; 2012; 7(8):e42866. PubMed ID: 22936996
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.
Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA
Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508
[TBL] [Abstract][Full Text] [Related]
10. Trends in Statin Use in Seniors 1999 to 2013: Time Series Analysis.
Minard LV; Corkum A; Sketris I; Fisher J; Zhang Y; Saleh A
PLoS One; 2016; 11(7):e0158608. PubMed ID: 27434392
[TBL] [Abstract][Full Text] [Related]
11. Statin Treatment and Clinical Outcomes of Heart Failure Among Africans: An Inverse Probability Treatment Weighted Analysis.
Bonsu KO; Owusu IK; Buabeng KO; Reidpath DD; Kadirvelu A
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28365564
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect.
Zhou Z; Rahme E; Abrahamowicz M; Tu JV; Eisenberg MJ; Humphries K; Austin PC; Pilote L
CMAJ; 2005 Apr; 172(9):1187-94. PubMed ID: 15851712
[TBL] [Abstract][Full Text] [Related]
13. Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis.
Cui JY; Zhou RR; Han S; Wang TS; Wang LQ; Xie XH
J Clin Pharm Ther; 2018 Aug; 43(4):556-570. PubMed ID: 29733433
[TBL] [Abstract][Full Text] [Related]
14. Statin-related neurocognitive disorder: a real-world pharmacovigilance study based on the FDA adverse event reporting system.
Xiao M; Li L; Zhu W; Wu F; Wu B
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):255-261. PubMed ID: 38275183
[TBL] [Abstract][Full Text] [Related]
15. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
[TBL] [Abstract][Full Text] [Related]
16. Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Huang BZ; Chang JI; Li E; Xiang AH; Wu BU
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040693
[TBL] [Abstract][Full Text] [Related]
17. Primary Prevention of Cardiocerebrovascular Diseases and Related Deaths According to Statin Type.
Kim J; Kim HS; Yang W; Lee JW; Kang HT
Int J Environ Res Public Health; 2020 Aug; 17(17):. PubMed ID: 32872631
[TBL] [Abstract][Full Text] [Related]
18. Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants.
Lönnberg KI; Tornio A; Hirvensalo P; Keskitalo J; Mustaniemi AL; Kiiski JI; Filppula AM; Niemi M
Pharmacogenet Genomics; 2023 Sep; 33(7):153-160. PubMed ID: 37490620
[TBL] [Abstract][Full Text] [Related]
19. Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study.
Anyanwagu U; Mamza J; Donnelly R; Idris I
Cardiovasc Diabetol; 2017 Aug; 16(1):107. PubMed ID: 28830436
[TBL] [Abstract][Full Text] [Related]
20. Protective Effects Against Dementia Undergo Different Statin Type, Intensity, and Cumulative Dose in Older Adult Type 2 Diabetes Mellitus Patients.
Sun M; Chen WM; Wu SY; Zhang J
J Am Med Dir Assoc; 2024 Mar; 25(3):470-479.e1. PubMed ID: 38128583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
